

**Inside this Edition**

Age Change..... 1

Begin Date Change..... 2

Category of Service..... 2

Classification..... 2

Codes..... 3

Coverage Codes..... 6

Modifiers..... 10

Place of Service..... 14

Prior Authorization..... 16

Procedure Code Indicators..... 16

Provider Type..... 17

**Age Changes**

The following codes have had the ages changed.

Code	Description	Minimum	Maximum
OUT10ZZ	Resection Of Left Ovary, Open Approach	009 Y	065 Y
OUT60ZZ	Resection Of Left Fallopian Tube, Open Approach	009 Y	065 Y
99188	Application Of Topical Fluoride	000 Y	005 Y
B4105	In-Line Cartridge Containing Digestive Enzyme(s) For Enteral Feeding, Each	000 Y	999 Y
P04.81	Newborn Affected by Maternal Use of Cannabis	000 Y	999 Y

- For changes for the ICD-10 codes that have had the age range changed to 009Y to 064Y refer to the Reference Screens.

**Begin Date Change**

The effective **begin date** has been changed to March 1, 2022, for provider types 18 (Physician’s Assistant) and 19 (Registered Nurse Practitioner) for the following codes.

- 96377 - Application of On-Body Injector for Under Skin Injection
- J2506 - Injection, Pegfilgrastim, Excludes Biosimilar, 0.5 mg
- J9316 - Injection, Pertuzumab, Trastuzumab, And Hyaluronidase-ZZXF, Per 10 mg

**Category of Service**

- Effective June 1, 2022, the following Codes have been changed from 15 (DME And Appliances) to Category of Service 40 (Medical Supplies).

Code	
B9002	Enteral Nutrition Infusion Pump, Any Type
B9004	Parenteral Nutrition Infusion Pump, Portable
B9006	Parenteral Nutrition Infusion Pump, Stationary
B9998	Noc For Enteral Supplies
B9999	Noc For Parenteral Supplies

- Category of Service 40 (Medical Supplies) has been **end dated** for B9000 (Enteral Nutrition Infusion Pump - Without Alarm).

**Classification**

The ICD-10 Diagnosis Code class codes for the following have been changed.

Code	Class	Code	Class	Code	Class
S04032	S00	S62622	S00	S63124	S00
S04039	S00	S62623	S00	S63125	S00
S04041	S00	S62624	S00	S63126	S00
S04042	S00	S62625	S00	S92522	S00
S04049	S00	S62650	S00	S92523	S00
S62311	S00	S62651	S00	S92524	S00
S62317	S00	S62652	S00	S92525	S00
S62341	S00	S62653	S00	S92526	S00
S62347	S00	S63121	S00	W298	V00
S62620	S00	S63122	S00		

**From the Coding Manager** - The JZ (Zero Drug Amount Discarded/Not Administered) modifier was added to the RF121 and RF122/132 screens for those codes that show status indicator K or G to align with the correct use of this modifier.

## Codes

Effective for dates listed, the following codes have been added to the Reference Screen.

Code	Description	Effective Begin Date
0019M	Cardiovascular Disease, Plasma, Analysis of Protein Biomarkers by Aptamer-Based Microarray and Algorithm Reported As 4-Year Likelihood of Coronary Event in High-Risk Population	10/01/2023
0402U	Infectious Agent (Sexually Transmitted Infection), Chlamydia Trachomatis, Neisseria Gonorrhoeae, Trichomonas Vaginalis, Mycoplasma Genitalium, Multiplex Amplified Probe Technique, Vaginal, Endocervical, Or Male Urine, Each Pathogen Reported as Detected or Not Detected	10/01/2023
0403U	Oncology (Prostate), MRNA, Gene Expression Profiling Of 18 Genes, First-Catch Post-Digital Rectal Examination Urine (Or Processed First-Catch Urine), Algorithm Reported as Percentage of Likelihood of Detecting Clinically Significant Prostate Cancer	10/01/2023
0404U	Oncology (Breast), Semiquantitative Measurement of Thymidine Kinase Activity by Immunoassay, Serum, Results Reported as Risk of Disease Progression	10/01/2023
0405U	Oncology (Pancreatic), 59 Methylation Haplotype Block Markers, Next-Generation Sequencing, Plasma, Reported as Cancer Signal Detected or Not Detected	10/01/2023
0406U	Oncology (Lung), Flow Cytometry, Sputum, 5 Markers (Meso-Tetra [4-Carboxyphenyl] Porphyrin [TCPP], CD206, CD66B, CD3, CD19), Algorithm Reported as Likelihood of Lung Cancer	10/01/2023
0407U	Nephrology (Diabetic Chronic Kidney Disease [CKD]), Multiplex Electrochemiluminescent Immunoassay (ECLIA) Of Soluble Tumor Necrosis Factor Receptor 1 (Stnfr1), Soluble Tumor Necrosis Receptor 2 (Stnfr2), And Kidney Injury Molecule 1 (Kim-1) Combined with Clinical Data, Plasma, Algorithm Reported as Risk for Progressive Decline in Kidney Function	10/01/2023
0408U	Infectious Agent Antigen Detection by Bulk Acoustic Wave Biosensor Immunoassay, Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [Covid-19])	10/01/2023
0409U	Oncology (Solid Tumor), DNA (80 Genes) And RNA (36 Genes), By Next-Generation Sequencing from Plasma, Including Single Nucleotide Variants, Insertions/Deletions, Copy Number Alterations, Microsatellite Instability, And Fusions, Report Showing Identified Mutations with Clinical Actionability	10/01/2023
0410U	Oncology (Pancreatic), DNA, Whole Genome Sequencing With 5-Hydroxymethylcytosine Enrichment, Whole Blood, or Plasma, Algorithm Reported as Cancer Detected or Not Detected	10/01/2023
0411U	Psychiatry (e.g., Depression, Anxiety, Attention Deficit Hyperactivity Disorder [ADHD]), Genomic Analysis Panel, Variant Analysis Of 15 Genes, Including Deletion/Duplication Analysis of Cyp2d6	10/01/2023
0412U	Beta Amyloid, Ab42/40 Ratio, Immunoprecipitation with Quantitation by Liquid Chromatography with Tandem Mass Spectrometry (LC-MS/MS) And Qualitative Apoe Isoform-Specific Proteotyping, Plasma Combined with Age, Algorithm Reported as Presence or Absence of Brain Amyloid Pathology	10/01/2023
0413U	Oncology (Hematolymphoid Neoplasm), Optical Genome Mapping for Copy Number Alterations, Aneuploidy, And Balanced/Complex Structural Rearrangements, DNA from Blood or Bone Marrow, Report of Clinically Significant Alterations	10/01/2023

Code	Description	Effective Begin Date
0414U	Oncology (Lung), Augmentative Algorithmic Analysis of Digitized Whole Slide Imaging For 8 Genes (ALK, BRAF, EGFR, ERBB2, MET, NTRK1-3, RET, ROS1), And KRAS G12c And Pd-L1, If Performed, Formalin-Fixed Paraffin-Embedded (FFPE) Tissue, Reported as Positive or Negative for Each Biomarker	10/01/2023
0415U	Cardiovascular Disease (Acute Coronary Syndrome [ACS]), IL-16, FAS, FASLIGAND, HGF, Ctnck, Eotaxin, And MCP-3 By Immunoassay Combined with Age, Sex, Family History, And Personal History of Diabetes, Blood, Algorithm Reported as A 5-Year (Deleted Risk) Score for Acs	10/01/2023
0416U	Infectious Agent Detection by Nucleic Acid (DNA), Genitourinary Pathogens, Identification Of 20 Bacterial and Fungal Organisms, Including Identification Of 20 Associated Antibiotic-Resistance Genes, If Performed, Multiplex Amplified Probe Technique, Urine	10/01/2023
0417U	Rare Diseases (Constitutional/Heritable Disorders), Whole Mitochondrial Genome Sequence with Heteroplasmy Detection and Deletion Analysis, Nuclear-Encoded Mitochondrial Gene Analysis Of 335 Nuclear Genes, Including Sequence Changes, Deletions, Insertions, And Copy Number Variants Analysis, Blood or Saliva, Identification and Categorization of Mitochondrial Disorder-Associated Genetic Variants	10/01/2023
0418U	Oncology (Breast), Augmentative Algorithmic Analysis of Digitized Whole Slide Imaging Of 8 Histologic and Immunohistochemical Features, Reported as A Recurrence Score	10/01/2023
0419U	Neuropsychiatry (e.g., Depression, Anxiety), Genomic Sequence Analysis Panel, Variant Analysis Of 13 Genes, Saliva or Buccal Swab, Report of Each Gene Phenotype	10/01/2023
91318	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 3 mcg/0.2 mL dosage, tris-sucrose formulation, for intramuscular use	09/11/2023
91319	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 10 mcg/0.2 mL dosage, tris-sucrose formulation, for intramuscular use	09/11/2023
91320	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	09/11/2023

- Effective October 1, 2023, the following HCPCS codes have been added to the Reference Screens.

Codes				
A2022	A9697	C9789	J0802	J9345
A2023	B4148	C9790	J0874	K1036
A2024	C9152	C9791	J0889	L1681
A2025	C9153	C9792	J2359	L5991
A9156	C9154	E0490	J2781	Q4285
A9268	C9155	E0491	J7214	Q4286
A9269	C9156	H2040	J7353	V2526
A9292	C9157	H2041	J7519	
A9573	C9158	J0349	J9051	
A9603	C9788	J0801	J9064	

### Code Changes

The below information has been added to HCPCS code J2781 (Injection, Pegcetacoplan, intravitreal, 1 mg) effective October 1, 2023.

Modifier SG - AMB SURG CTR (ASC) FA  
 Place of Service 24 - Ambulatory Surgical Center  
 Provider Type 43 - Ambulatory Surgical Center  
 Revenue Code 0490 - AMBUL SURG

## Coverage Codes

- The following codes have a coverage code change.

Code	Description	Coverage Code	Effective Begin Date
D0367	Cone Beam Ct Capture and Interpretation with Field of View of Both Jaws, With or Without Cranium	03 - PA Required for Both Acute And LTC	08/24/2023
A9603	Injection, Pafolacianine, 0.1 m	01 - Covered Service/Code Available	10/1/2023
C9151	Injection, Pegcetacoplan, 1mg	01 - Covered Service/Code Available	10/1/2023
J0800	Injection, Corticotropin, up to 40 units	04 - Not Covered Service/Code Not Available	10/1/2023
0052U	Measurement of All Five Major Lipoprotein Classes and Subclasses in Blood	04 - Not Covered Service/Code Not Available	8/1/2023
90480	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, single dose	01 - Covered Service/Code Available	9/11/2023
90480	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, single dose	01 - Covered Service/Code Available	9/11/2023
91321	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use	01 - Covered Service/Code Available	9/11/2023
91322	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use	03 - Covered Service/Use Other Code	9/11/2023
98960	Education And Training for Patient Self-Management, Each 30 Minutes	01 - Covered Service/Code Available	04/01/2023
98961	Education And Training for Patient Self-Management, 2-4 Patients, Each 30 Minutes	01 - Covered Service/Code Available	04/01/2023
98962	Education And Training for Patient Self-Management, 5-8 Patients, Each 30 Minutes	01 - Covered Service/Code Available	04/01/2023

- There will be an update to Proprietary Laboratory Analyses (PLA) codes (those ending in U). The following codes will be closed effective 9/1/2023 after an internal review. The code listed will have Coverage Code 04 (Not Covered Service/Code Not Available) effective 9/1/2023 to 99/99/9999.

Codes			
0048U	0105U	0258U	0311U
0062U	0108U	0259U	0314U
0063U	0112U	0260U	0317U
0064U	0166U	0261U	0320U
0067U	0167U	0282U	0323U
0070U	0171U	0288U	0324U
0078U	0179U	0291U	0325U
0082U	0213U	0294U	0330U
0086U	0239U	0304U	0341U
0087U	0246U	0305U	0346U
0088U	0251U	0306U	0349U
0091U	0254U	0307U	0351U
0095U	0257U	0308U	0366U

- Effective October 31, 2023, the Coverage code 01 (Covered Service/Code Available) or 03 (Covered Service/Use Other Code) will be end dated. Note: 03 Coverage Codes have a \* after the code.
- The coverage Code 04 (Not Covered Service/Code Not Available) will begin November 1, 2023.

Code	Description
0041A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; first dose
0042A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; second dose
0044A	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage, for intramuscular use. Booster
0121A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; single dose
0124A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, booster dose
0134A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, booster dose
0141A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage; first dose
0142A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage; second dose
0144A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNALNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, booster dose
0151A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation: single dose
0154A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, booster dose
0164A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, booster dose



Code	Description
0171A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation: first dose
0172A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation: second dose
0173A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, third dose
0174A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation: booster dose
91312*	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, trissucrose formulation, for intramuscular use
91313*	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free 50 mcg/0.5 mL dosage, for intramuscular use
91314*	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free 50 mcg/0.5 mL dosage, for intramuscular use
91315*	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use
91316*	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, for intramuscular use
91317*	Severe acute respiratory syndrome coronavirus 2 (SARS -CoV-2) (coronavirus disease [COVID -19]) vaccine, mRNA -LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris -sucrose formulation, for intramuscular use

## Modifiers

- From Coding Manager - The JZ (Zero Drug Amount Discarded/Not Administered) modifier was added to the RF121 and RF122/132 screens for those codes that show status indicator K or G to align with the correct use of this modifier.
- Effective for dates listed the following CPT/HCPCS codes have had the modifiers added to the Reference Screens.

Code	Description	Modifiers	Effective Begin Date
87502	Detection Test by Nucleic Acid for Multiple Types Influenza Virus	ER - RES-DOM FAC-RES/ITMS-SVS	1/1/2023
87634	Detection Test by Nucleic Acid for Respiratory Syncytial Virus, Amplified Probe Technique	ER - RES-DOM FAC-RES/ITMS-SVS	1/1/2023
87651	Detection Test by Nucleic Acid for Strep (Streptococcus, Group A), Amplified Probe Technique	ER - RES-DOM FAC-RES/ITMS-SVS	1/1/2023
90675	Rabies Vaccine for Injection into Muscle	JZ - Zero Drug Amount Discarded/Not Administered	1/1/2023
93005	Routine Electrocardiogram (ECG) Using At Least 12 Leads with Tracing	GC -Teaching Physician Service	1/1/2023
94640	Inhalation Treatment for Airway Obstruction or Sputum Production	ER - RES-DOM FAC-RES/ITMS-SVS	1/1/2023
97129	Therapy Procedure for A Range of Mental Processes, Initial 15 Minutes	GN - AMB HSP 2SNF/OP Speech L	1/1/2023
97130	Therapy Procedure for A Range of Mental Processes, Each Additional 15 Minutes	GN - AMB HSP 2SNF/OP Speech L	1/1/2023
99233	Subsequent Hospital Care with Moderate Level of Medical Decision Making, If Using Time, at least 50 Minutes	Q1 - Routine CLIN Research/Cert Mycosis Toenail	1/1/2023
A9279	Monitoring Feature/Device, Stand-Alone or Integrated, Any Type,	KH - DMEPOS Item, INIT CLM	1/1/2023
E0766	Electrical Stimulation Device Used for Cancer Treatment, Includes All Accessories, Any Type	KY - DMEPOS COMP Bid Program No 5	1/1/2022
E0766	Electrical Stimulation Device Used for Cancer Treatment, Includes All Accessories, Any Type	KX - Requirements Specified in The Medical Po	1/1/2022
E0766	Electrical Stimulation Device Used for Cancer Treatment, Includes All Accessories, Any Type	KY - DMEPOS COMP Bid Program No 5	1/1/2022
E0766	Electrical Stimulation Device Used for Cancer Treatment, Includes All Accessories, Any Type	KX - Requirements Specified in The Medical Po	1/1/2022
E0951	Heel Loop/Holder, Any Type, With or Without Ankle Strap	KX - Requirements Specified in The Medical Po	1/1/2022
E0955	Wheelchair Accessory, Headrest, Cushioned, Any Type	KX - Requirements Specified in The Medical Po KX	1/1/2023
E1028	Wheelchair Accessory, Manual Swing away, Retractable or Removable	KX - Requirements Specified in The Medical Po	1/1/2023
E2201	Manual Wheelchair Accessory, Nonstandard Seat Frame,	KX - Requirements Specified in The Medical Po	1/1/2023

Code	Description	Modifiers	Effective Begin Date
E2203	Manual Wheelchair Accessory, Nonstandard Seat Frame Depth, 20 To Less Than 22 Inches	KX - Requirements Specified in The Medical Po	1/1/2023
E2211	Manual Wheelchair Accessory, Pneumatic Propulsion Tire, Any Size,	KX - Requirements Specified in The Medical Po	1/1/2023
E2213	Manual Wheelchair Accessory, Insert for Pneumatic Propulsion Tire (Removable)	KX - Requirements Specified in The Medical Po	1/1/2023
E2601	General Use Wheelchair Seat Cushion, Width Less Than 22 Inches, Any Depth	KX - Requirements Specified in The Medical Po	1/1/2023
E2611	General Use Wheelchair Back Cushion, Width Less Than 22 Inches,	KX - Requirements Specified in The Medical Po	1/1/2023
J0129	Injection, Abatacept, 10 mg	JZ - Zero Drug Amount Discarded/Not Administered	1/1/2023
J0178	Injection, Aflibercept, 1 mg	JZ - Zero Drug Amount Discarded/Not Administered	1/1/2023
J0185	Injection, Aprepitant, 1 mg	JZ - Zero Drug Amount Discarded/Not Administered	1/1/2023
J0223	Injection, Givosiran, 0.5 mg	JW - Drug Amt Discarded/Not Admin to Any Pati	10/1/2022
J0490	Injection, Belimumab, 10 mg	JZ - Zero Drug Amount Discarded/Not Administered	1/1/2023
J0561	Injection, Penicillin G Benzathine, 100,000 Units	JZ - Zero Drug Amount Discarded/Not Administered	1/1/2023
J0585	Injection, Onabotulinumtoxin A, 1 Unit	JZ - Zero Drug Amount Discarded/Not Administered	1/1/2023
J0717	Injection, Certolizumab Pegol, 1 mg	JZ - Zero Drug Amount Discarded/Not Administered	1/1/2023
J0878	Injection, Daptomycin, 1 mg	JZ - Zero Drug Amount Discarded/Not Administered	1/1/2023
J0897	Injection, Denosumab, 1 mg	JZ - Zero Drug Amount Discarded/Not Administered	1/1/2023
J0897	Injection, Denosumab, 1 mg	JZ - Zero Drug Amount Discarded/Not Administered	7/1/2023
J1096	Dexamethasone, Lacrimal Ophthalmic Insert, 0.1 mg	JZ - Zero Drug Amount Discarded/Not Administered	7/1/2023
J1097	Phenylephrine 10.16 mg/ml and Ketorolac 2.88 mg/ml Ophthalmic Irrigation Solution, 1 ml	JZ - Zero Drug Amount Discarded/Not Administered	7/1/2023
J1100	Injection, Dexamethasone Sodium Phosphate, 1 mg	ER - Res-Dom Fac-Res/Itms-Svs	1/1/2023
J1162	Injection, Digoxin Immune Fab (Ovine), Per Vial	JZ - Zero Drug Amount Discarded/Not Administered	1/1/2023
J1300	Injection, Eculizumab, 10 mg	JZ - Zero Drug Amount Discarded/Not Administered	1/1/2023
J1442	Injection, Filgrastim (G-CSF), Excludes Biosimilars, 1 microgram	JZ - Zero Drug Amount Discarded/Not Administered	1/1/2023

Code	Description	Modifiers	Effective Begin Date
J1561	Injection, Immune Globulin, (Gamunex-C/Gammaked), Non-Lyophilized (e.g., Liquid), 500 mg	JZ - Zero Drug Amount Discarded/Not Administered	7/1/2023
J2353	Injection, Octreotide, Depot Form for Intramuscular Injection, 1 mg	JZ - Zero Drug Amount Discarded/Not Administered	7/1/2023
J2777	Injection, Faricimab-Svoa, 0.1 mg	JZ - Zero Drug Amount Discarded/Not Administered	1/1/2023
J2778	Injection, Ranibizumab, 0.1 mg	JZ - Zero Drug Amount Discarded/Not Administered	1/1/2023
J3032	Injection, Eptinezumab-JJMR, 1 mg	JZ - Zero Drug Amount Discarded/Not Administered	1/1/2023
J3101	Injection, Tenecteplase, 1 mg	JW - Drug Amount Discarded/Not Admin to any Pati	1/1/2023
J3380	Injection, Vedolizumab, 1 mg	JZ - Zero Drug Amount Discarded/Not Administered	1/1/2023
J3420	Injection, Vitamin B-12 Cyanocobalamin, Up To 1000 mcg	JZ - Zero Drug Amount Discarded/Not Administered	7/1/2023
J3475	Injection, Magnesium Sulfate, Per 500 mg	JA - Administered Intravenously	7/1/2023
J7312	Injection, Dexamethasone, Intravitreal Implant, 0.1 mg	JZ - Zero Drug Amount Discarded/Not Administered	1/1/2023
J9035	Injection, Bevacizumab, 10 mg	JZ - Zero Drug Amount Discarded/Not Administered	1/1/2023
J9217	Leuprolide Acetate (For Depot Suspension), 7.5 mg	JZ - Zero Drug Amount Discarded/Not Administered	1/1/2023
J9271	Injection, Pembrolizumab, 1 mg	JZ - Zero Drug Amount Discarded/Not Administered	7/1/2023
J9297	Injection, Nivolumab and Relatlimab-RMBW, 3 mg/1 mg	JW - Drug Amount Discarded/Not Admin to any Pati	4/1/2023
J9306	Injection, Pertuzumab, 1 mg	JZ - Zero Drug Amount Discarded/Not Administered	1/1/2023
J9358	Injection, Fam-Trastuzumab Deruxtecan-Nxki, 1 mg	JZ - Zero Drug Amount Discarded/Not Administered	7/1/2023
K0108	Wheelchair Component or Accessory, Not Otherwise Specified	KX - Requirements Specified in The Medical Po	7/1/2023
P9045	Infusion, Albumin (Human), 5%, 250 ml	JZ - Zero Drug Amount Discarded/Not Administered	1/1/2023
Q5106	Injection, Epoetin ALFA-EPBX, Biosimilar, (RETACRIT) (for Non-ESRD use), 1000 units	JZ - Zero Drug Amount Discarded/Not Administered	1/1/2023
Q5107	Injection, Bevacizumab-AWWB, Biosimilar, (MVASI), 10 mg	JZ - Zero Drug Amount Discarded/Not Administered	1/1/2023
Q5114	Injection, Trastuzumab-Dkst, Biosimilar, (OGIVRI), 10 m	JZ - Zero Drug Amount Discarded/Not Administered	1/1/2023
Q5118	Injection, Bevacizumab-Bvzr, Biosimilar, (Zirabev), 10 mg	JZ - Zero Drug Amount Discarded/Not Administered	1/1/2023
Q5120	Injection, Pegfilgrastim-Bmez, Biosimilar, (Ziextenzo), 0.5 mg	JZ - Zero Drug Amount Discarded/Not Administered	1/1/2023

Code	Description	Modifiers	Effective Begin Date
Q5124	Injection, Ranibizumab-Nuna, Biosimilar, (Byooviz), 0.1 mg	JZ - Zero Drug Amount Discarded/Not Administered	1/1/2023
Q5128	Injection, Ranibizumab-Eqrn (Cimerli), Biosimilar, 0.1 mg	JZ - Zero Drug Amount Discarded/Not Administered	1/1/2023

**Modifier End Date**

- Modifier 50 (Bilateral Procedure (Pay 50%)) has been **end dated** effective October 1, 2023 for the following codes on the reference screen RF121.

Codes			
19000	31624	32673	52005
19001	31626	32674	95907

- Effective October 1, 2023, the modifier 50 (Bilateral Procedure (Pay 50%)) has been **end dated** for the following codes on RF122 and RF132.

19294	32098	58356
21470	32560	67320
26111	35111	73060
26113	36589	76881
26118	38589	76882
30300	42665	95905
31624	52334	0442T
31626	52351	0553T

Place of Service (POS)

The following POS has been added to the codes listed.

Code	Description	Place of Service	Effective Begin Date
30469	Repair Of Collapsed Nasal Valve	11 - Office	01/01/2023
88184	Flow Cytometry Technique for DNA or Cell Analysis, First Marker	21 - Inpatient Hospital	10/01/2022
93460	Insertion Of Tube in Right and Left Heart Chambers and Coronary Artery for Diagnosis with Review by Radiologist	23 - Emergency Room - Hospital	07/01/2023
93505	Biopsy Of Heart Muscle	23 - Emergency Room - Hospital	07/01/2023
97150	Therapy Procedure in A Group Setting	57 - Non-Residential Substance Abuse Treatment	01/012023
97151	Behavior Identification Assessment by Professional, Each 15 Minutes	14 - Group Home	04/01/2023
97153	Adaptive Behavior Treatment by Technician Using an Established Plan, Each 15 Minutes	14 - Group Home	04/01/2023
97155	Adaptive Behavior Treatment by Professional Using an Established Plan, Each 15 Minutes	14 - Group Home	04/01/2023
97156	Adaptive Behavior Treatment by Professional with Family Using an Established Plan, Each 15 Minutes	14 - Group Home	04/01/2023
99341	Residence Visit for New Patient with Straigh Per Day, If Using Time, at least 15 Minutes	57 - Non-Residential Substance Abuse Treatment	01/012023
99342	Residence Visit for New Patient with Low Level of Medical Decision Making, Per Day, If Using Time, at Least 30 Minutes	57 - Non-Residential Substance Abuse Treatment	01/012023
99344	Residence Visit for New Patient with Moderate Level of Medical Decision Making, Per Day, If Using Time, at Least 60 Minutes	57 - Non-Residential Substance Abuse Treatment	01/012023
99345	Residence Visit for New Patient with High Level of Medical Decision Making, Per Day, If Using Time, at least 75 Minutes	57 - Non-Residential Substance Abuse Treatment	01/012023
99347	Residence Visit for Established Patient with Straightforward Medical Decision Making, Per Day, If Using Time, at least 15 Minutes	57 - Non-Residential Substance Abuse Treatment	01/012023
99348	Residence Visit for Established Patient with Low Level of Medical Decision Making, Per Day, If Using Time, at least 30 Minutes	57 - Non-Residential Substance Abuse Treatment	01/012023
99349	Residence Visit for Established Patient with Moderate Level of Medical Decision Making, Per Day, If Using Time, at least 40 Minutes	57 - Non-Residential Substance Abuse Treatment	01/012023

Code	Description	Place of Service	Effective Begin Date
99350	Residence Visit for Established Patient with High Level of Medical Decision Making, Per Day, If Using Time, at least 60 Minutes	57 - Non-Residential Substance Abuse Treatment	01/01/2023
D7270	Tooth Reimplantation and/or Stabilization of Accidentally Evulsed or Displaced Tooth	23 - Emergency Room - Hospital	07/01/2023
E2103	Non-Adjunctive, Non-Implanted Continuous Glucose Monitor or Receiver	12 - Home	01/01/2023
G0127	Trimming Of Dystrophic Nails, Any Number	13 - Assisted Living Facility	01/01/2023
J0699	Injection, Cefiderocol, 10 mg	12 - Home	05/01/2023

**PROCEDURE CODE INDICATORS AND VALUES**

Code	Description	Procedure Daily Maximum	EPSDT Indicator
A4225	Supplies for External Insulin Infusion Pump, Syringe Type Cartridge, Sterile, each	100	
92607	Evaluation with Prescription of Speech-Generating and Alternative Communication Device, First Hour		Y
92608	Evaluation with Prescription of Speech-Generating and Alternative Communication Device, Each Additional 30 minutes		Y
92609	Therapy Service for Use of Speech-Generating Device with Programming		Y

Note: A4225 under Laboratory Limit #1 = 100; Frequency #1 = 1 M

**Prior Authorization**

- D0367 (Cone Beam CT Capture and Interpretation with Field of VI) coverage is for Prior Authorization (RF124 Screen) code 03 (PA REQ'D FOR Both Acute & LTC) effective 08/24/2023.
- Effective April 1, 2022, the HCPCS code J9273 (Injection, Tisotumab Vedotin-TFTV, 1 mg) has a Prior Authorization code of 04 (PA Not Required for Acute or LTC).



**Procedure Daily Maximum**

Code	Description	Procedure Daily Maximum
64420	Injection Of Anesthetic Agent And/or Steroid into Rib Nerve	1
97036	Application Of Water Therapy Using a Special Tank, Each 15 Minutes	3
97803	Therapy Procedure Reassessment for Nutrition Management, Each 15 Minutes	11
A9607	Lutetium Lu 177 Vipivotide Tetraxetan, Therapeutic, 1 Millicurie	200
D0367	Cone Beam Ct Capture and Interpretation with Field of View of Both Jaws, With or Without Cranium)	1
J1569	Injection, Immune Globulin, (Gammagard Liquid), Non-Ly	400

- The HCPCS code D0367 (Cone Beam Ct Capture and Interpretation with Field of View of Both Jaws, With or Without Cranium) changes for the Laboratory Limit is one (1) and the Frequency is 004 Y.

**Provider Type**

- Effective August 31, 2023, the HCPCS code S9470 (Nutritional Counseling, Dietitian Visit) has been end dated for the following providers.

02 - Hospital	31 - DO-Physician Osteopath
05 – Clinic	47 - Registered Dietician
08 - MD-Physician	48 - Nutritionist
18 - Physician’s Assistant	CN - Clinical Nurse Specialist
19 - Registered Nurse Practitioner	IC - Integrated Clinics

- The PHE ended and with it some of its flexibility. This includes returning rates back to .90 percent on the mid-levels (CN, PA, NP) effective 5/12/2023.
- Effective January 1, 2023, the following codes have been added to the provider types listed.

17106	Destruction Of Birthmark, Less Than 10.0 sq cm	19 - Registered Nurse Practitioner
L8692	Auditory Osseointegrated Device, External Sound Processor, Used Without Osseointegration, Body Worn, Includes Headband or Other Means of External Attachment	62 - Audiologist

- The end date for the HCPCS code S9470 (Nutritional Counseling, Dietitian Visit) has been changed to 99/99/9999 for the providers: 48 – Nutritionist, 47- Registered Dietician IC- Integrated Clinics